[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"randomized-controlled-trials\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:randomized-controlled-trials":44},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,58,88],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":50,"completionDateStruct":52,"leadSponsor":54,"locationsCount":57},"100610370","phase-3-suzetrigine-in-total-hip-arthroplasty-100610370",false,"NCT07226700","Suzetrigine in Total Hip Arthroplasty","A Randomized, Placebo-controlled, Double-blind Trial of Suzetrigine in Total Hip Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary THA (posterior approach) with participating surgeons\n* Age 18 to 80 years old\n* Planned discharge to home\n* Planned use of neuraxial anesthesia\n* American Society of Anesthesiologists (ASA) Physical Status 1 - 3\n\nExclusion Criteria:\n\n* ASA greater than 3\n* Chronic opioid use (daily MME of greater than 30 mg for at least 3 months and within 1 month of surgery)\n* History of chronic pain syndromes or uncontrolled pain (i.e. complex regional pain syndrome, fibromyalgia, implanted spinal cord stimulator)\n* History of QT prolongation\n* Presence of automated implantable cardioverter defibrillator, pacemaker or cardiac resynchronization device\n* Evidence of misuse, aberrant use, or addiction to alcohol or an illicitly used drug of abuse, or had a positive test for drugs of abuse\n* Inability to comply with any component of the study protocol\n* Younger than 18 or greater than 80 years old at the time of enrollment\n* Patient already on Suzetrigine\n* Allergy or contraindication to Suzetrigine or excipients (eg moderate to severe liver disease\u002FChild Pugh B or C, use of strong CYP3 inhibitors or inducers)\n* Contraindications to neuraxial anesthesia or any other part of the study protocol\n* Participation in another investigational drug or device study\n* Pregnancy",true,"ALL","18 Years","80 Years",{"count":21,"type":22},210,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Total hip and knee joint replacements are among the most common and painful orthopedic procedures performed worldwide, often requiring intensive analgesia to support early ambulation and recovery. Despite widespread use of multimodal regimens, many patients still rely on opioids, which can cause sedation, nausea, constipation, and long-term dependency. Evaluating Suzetrigine in this high-need population may improve recovery trajectories, reduce opioid consumption, and support enhanced recovery protocols. Given the growing surgical volume and the emphasis on opioid-sparing strategies, rigorous investigation of Suzetrigine's efficacy in joint replacement is of high clinical value. In this study, patients undergoing primary total hip replacement will be randomized to receive either Suzetrigine or placebo for seven days, with the loading dose administered prior to surgery. The primary outcome is cumulative 48-hour opioid consumption in oral morphine equivalents starting from entry into the post-anesthesia care unit (PACU).",[28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Total Hip Arthroplasty (THA)","Total Hip Arthroplasty \\(THA\\)","Total Hip Replacement","Total Hip Replacement Surgery","Total Hip Replacements","Total Hip Replacement Arthroplasty","Suzetrigine","Pain Management","Pain","Nav 1.8","JOURNAVX","Opioid Cessation","Opioid Consumption, Postoperative","Multimodal Analgesia","Randomized Controlled Trial","Randomized Controlled Study","Randomized Controlled Trials","RECRUITING","2026-06-02",{"date":48,"type":49},"2026-06-03","ACTUAL",{"date":51,"type":49},"2025-11-03",{"date":53,"type":22},"2028-11-01",{"name":55,"class":56},"Hospital for Special Surgery, New York","OTHER",1,{"id":59,"slug":60,"hasResults":11,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":64,"eligibilityCriteria":65,"healthyVolunteers":16,"sex":17,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":23,"phases":70,"briefSummary":72,"conditions":73,"keywords":4,"overallStatus":45,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":57},"100625823","effect-of-visual-deprivation-of-the-team-leader-on-team-performance-during-simulated-medical-emergencies-100625823","NCT07427641","Effect of Visual Deprivation of the Team Leader on Team Performance During Simulated Medical Emergencies","LEADE ME: Effect of Visual Deprivation of the Team Leader on Team Performance During Simulated Medical Emergencies - A Multicenter Randomized Controlled Study","LEAD ME","The teams participating in the simulation sessions are composed as follows:\n\n* A senior doctor identified as the \"medical leader\"\n* An anaesthesia and intensive care intern\n* A state-registered nurse anaesthetist\n\nInclusion Criteria:\n\n1. Participants with at least two years' experience in the specialty.\n\n   a. For interns, an additional requirement is that they must have completed a semester in intensive care.\n2. Recruited via simulation trainers at their respective hospitals or university hospitals.\n\nExclusion Criteria:\n\n* The study cannot be carried out during a safety rest period (i.e. the day after being on call).","25 Years","65 Years",{"count":69,"type":22},54,[71],"NA","This multicenter randomized controlled study aims to evaluate the impact of temporary visual deprivation of the medical team leader on non-technical skills and team performance during high-fidelity simulated medical emergencies. The intervention is based on principles of crisis resource management and cognitive load theory. Team performance will be assessed using validated scoring tools immediately after the intervention and at three months follow-up.",[74,44,75,76,77,78],"High Fidelity Simulation Training","Education, Medical, Continuing","Education, Medical","Teaching Innovation","Competency Based Education","2026-03-30",{"date":81,"type":49},"2026-03-31",{"date":83,"type":49},"2026-02-02",{"date":85,"type":22},"2027-04",{"name":87,"class":56},"Rennes University Hospital",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":16,"sex":17,"minAge":95,"maxAge":96,"enrollmentInfo":97,"targetDuration":4,"studyType":23,"phases":99,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":106,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":57},"100564762","effect-of-a-myopia-prediction-system-on-myopia-prevention-and-control-100564762","NCT06633393","Effect of a Myopia Prediction System on Myopia Prevention and Control","Impact of Feedback Based on the Myopia Prediction System on High Myopia Risk and Consultation Behavior in School-aged Children: a Cluster Randomized Controlled Trial","Inclusion Criteria:\n\n* The participant and their guardian voluntarily signed the informed consent form\n* Has the record of eye refraction examination in the past year\n* Aged 9 to 11 years, regardless of gender\n\nExclusion Criteria:\n\n* High myopia(spherical equivalent ≤ -6.00 D)\n* Ocular diseases other than myopia (e.g., strabismus, amblyopia, congenital cataract, juvenile glaucoma, retinal diseases).\n* Systemic diseases that may affect vision or visual development (e.g., diabetes or other endocrine disorders, cardiovascular or respiratory diseases, Down syndrome)","9 Years","11 Years",{"count":98,"type":22},20000,[71],"The global rise in myopia, particularly among children and adolescents in China, underscores the inadequacy of current prevention strategies, indicating that conventional screening and education alone are insufficient to curb the prevalence. Integrating personalized myopia prediction into routine care may enhance risk awareness, promote proactive prevention, and improve adherence to medical advice, ultimately reducing the future burden of high myopia.\n\nA myopia prediction system based on artificial intelligence was previously developed, accurately predicting future high myopia risk using efficient, robust, and easily accessible predictive factors, including age, spherical equivalent, and the annual progression of spherical equivalent. This study aims to conduct a prospective, one-year, cluster randomized controlled clinical trial to investigate the effectiveness of this prediction system in preventing and controlling myopia in school-aged children.",[102,44,103],"Myopia","Artificial Intelligence (AI)",[105,44,103],"Myopia Prediction","NOT_YET_RECRUITING","2024-10-09",{"date":109,"type":49},"2024-10-15",{"date":111,"type":22},"2024-11-01",{"date":113,"type":22},"2026-02-28",{"name":115,"class":56},"Zhongshan Ophthalmic Center, Sun Yat-sen University"]